Literature DB >> 26232166

Utility of a genetic risk score to predict recurrent cardiovascular events 1 year after an acute coronary syndrome: A pooled analysis of the RISCA, PRAXY, and TRIUMPH cohorts.

Christopher Labos1, Sara C Martinez2, Rui Hao Leo Wang3, Petra A Lenzini4, Louise Pilote5, Peter Bogaty6, James M Brophy7, James C Engert8, Sharon Cresci9, George Thanassoulis10.   

Abstract

BACKGROUND: Limited evidence exists regarding the utility of genetic risk scores (GRS) in predicting recurrent cardiovascular events after acute coronary syndrome (ACS). We sought to determine whether a GRS would predict early recurrent cardiovascular events within 1 year of ACS. METHODS &
RESULTS: Participants admitted with acute coronary syndromes from the RISCA, PRAXY, and TRIUMPH cohorts, were genotyped for 30 single nucleotide polymorphisms (SNPs) associated with coronary artery disease (CAD) or myocardial infarction (MI) in prior genome wide association studies. A 30 SNP CAD/MI GRS was constructed. The primary endpoint was defined as all-cause mortality, recurrent ACS or cardiac re-hospitalization within 1 year of ACS admission. Results across all cohorts for the 30 SNP CAD/MI GRS were pooled using a random-effects model. There were 1040 patients from the RISCA cohort, 691 patients from the PRAXY cohort, and 1772 patients from the TRIUMPH cohort included in the analysis and 389 occurrences of the primary endpoint of recurrent events at 1-year post-ACS. In unadjusted and fully adjusted analyses, a 30 SNP GRS was not significantly associated with recurrent events (HR per allele 0.97 (95%CI 0.91-1.03) for RISCA, HR 0.99 (95%CI 0.93-1.05) for PRAXY, 0.98 (95%CI 0.94-1.02) for TRIUMPH, and 0.98 (95%CI 0.95-1.01) for the pooled analysis). Addition of this GRS to the GRACE risk model did not significantly improve risk prediction.
CONCLUSION: The 30 MI SNP GRS was not associated with recurrent events 1-year post ACS in pooled analyses across cohorts and did not improve risk discrimination or reclassification indices. Our results suggest that the genetic etiology of early events post-ACS may differ from later events.
Copyright © 2015 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Acute coronary syndrome; Genetic risk score; Risk prediction

Mesh:

Substances:

Year:  2015        PMID: 26232166      PMCID: PMC4772857          DOI: 10.1016/j.atherosclerosis.2015.07.029

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN: 0021-9150            Impact factor:   5.162


  38 in total

1.  Useful tests of usefulness of new risk factors: tools for assessing reclassification and discrimination.

Authors:  Johan Sundström; Liisa Byberg; Rolf Gedeborg; Karl Michaëlsson; Lars Berglund
Journal:  Scand J Public Health       Date:  2011-01-26       Impact factor: 3.021

2.  Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers.

Authors:  Michael J Pencina; Ralph B D'Agostino; Ewout W Steyerberg
Journal:  Stat Med       Date:  2010-11-05       Impact factor: 2.373

3.  GENESIS-PRAXY (GENdEr and Sex determInantS of cardiovascular disease: From bench to beyond-Premature Acute Coronary SYndrome).

Authors:  Louise Pilote; Igor Karp
Journal:  Am Heart J       Date:  2012-05       Impact factor: 4.749

4.  Influence of 23 coronary artery disease variants on recurrent myocardial infarction or cardiac death: the GRACE Genetics Study.

Authors:  Els Wauters; Kathryn F Carruthers; Ian Buysschaert; Donald R Dunbar; Gilian Peuteman; Ann Belmans; Andrzej Budaj; Frans Van de Werf; Diether Lambrechts; Keith A A Fox
Journal:  Eur Heart J       Date:  2012-11-15       Impact factor: 29.983

5.  Translational Research Investigating Underlying Disparities in Acute Myocardial Infarction Patients' Health Status (TRIUMPH): design and rationale of a prospective multicenter registry.

Authors:  Suzanne V Arnold; Paul S Chan; Philip G Jones; Carole Decker; Donna M Buchanan; Harlan M Krumholz; P Michael Ho; John A Spertus
Journal:  Circ Cardiovasc Qual Outcomes       Date:  2011-07

6.  Patients with premature cardiovascular disease and a positive family history for cardiovascular disease are prone to recurrent events.

Authors:  Ties A Mulders; Zainna Meyer; Christel van der Donk; Abraham A Kroon; Isabel Ferreira; Coen D A Stehouwer; Sara-Joan Pinto-Sietsma
Journal:  Int J Cardiol       Date:  2010-09-09       Impact factor: 4.164

7.  A genome-wide association study in Europeans and South Asians identifies five new loci for coronary artery disease.

Authors: 
Journal:  Nat Genet       Date:  2011-03-06       Impact factor: 38.330

8.  Genetic risk prediction and a 2-stage risk screening strategy for coronary heart disease.

Authors:  Emmi Tikkanen; Aki S Havulinna; Aarno Palotie; Veikko Salomaa; Samuli Ripatti
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-04-18       Impact factor: 8.311

9.  A composite scoring of genotypes discriminates coronary heart disease risk beyond conventional risk factors in the Boston Puerto Rican Health Study.

Authors:  M Junyent; K L Tucker; J Shen; Y-C Lee; C E Smith; J Mattei; C-Q Lai; L D Parnell; J M Ordovas
Journal:  Nutr Metab Cardiovasc Dis       Date:  2009-06-05       Impact factor: 4.222

Review 10.  Genetic variants at chromosome 9p21 and risk of first versus subsequent coronary heart disease events: a systematic review and meta-analysis.

Authors:  Riyaz S Patel; Folkert W Asselbergs; Arshed A Quyyumi; Tom M Palmer; Chris I Finan; Vinicius Tragante; John Deanfield; Harry Hemingway; Aroon D Hingorani; Michael V Holmes
Journal:  J Am Coll Cardiol       Date:  2014-03-07       Impact factor: 24.094

View more
  9 in total

Review 1.  Genetic Risk Prediction for Primary and Secondary Prevention of Atherosclerotic Cardiovascular Disease: an Update.

Authors:  Christopher Labos; George Thanassoulis
Journal:  Curr Cardiol Rep       Date:  2018-03-24       Impact factor: 2.931

Review 2.  Leveraging information from genetic risk scores of coronary atherosclerosis.

Authors:  Themistocles L Assimes; Elias L Salfati; Liana C Del Gobbo
Journal:  Curr Opin Lipidol       Date:  2017-04       Impact factor: 4.776

Review 3.  Implementing genomics and pharmacogenomics in the clinic: The National Human Genome Research Institute's genomic medicine portfolio.

Authors:  Teri A Manolio
Journal:  Atherosclerosis       Date:  2016-08-26       Impact factor: 5.162

4.  Missing single nucleotide polymorphisms in Genetic Risk Scores: A simulation study.

Authors:  Miguel Chagnon; Jennifer O'Loughlin; James C Engert; Igor Karp; Marie-Pierre Sylvestre
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

Review 5.  Genetic Risk Score for Coronary Heart Disease: Review.

Authors:  Sergey Semaev; Elena Shakhtshneider
Journal:  J Pers Med       Date:  2020-11-20

6.  Common genetic variants do not predict recurrent events in coronary heart disease patients.

Authors:  P L Thompson; J Hui; J Beilby; L J Palmer; G F Watts; M J West; A Kirby; S Marschner; R J Simes; D R Sullivan; H D White; R Stewart; A M Tonkin
Journal:  BMC Cardiovasc Disord       Date:  2022-03-09       Impact factor: 2.298

7.  Associations between polygenic risk of coronary artery disease and type 2 diabetes, lifestyle, and cardiovascular mortality: A prospective UK Biobank study.

Authors:  Jae-Seung Yun; Sang-Hyuk Jung; Manu Shivakumar; Brenda Xiao; Amit V Khera; Woong-Yang Park; Hong-Hee Won; Dokyoon Kim
Journal:  Front Cardiovasc Med       Date:  2022-08-17

8.  The GEnetic Syntax Score: a genetic risk assessment implementation tool grading the complexity of coronary artery disease-rationale and design of the GESS study.

Authors:  Ioannis S Vizirianakis; Fani Chatzopoulou; Andreas S Papazoglou; Efstratios Karagiannidis; Georgios Sofidis; Nikolaos Stalikas; Christos Stefopoulos; Konstantinos A Kyritsis; Nikolaos Mittas; Nikoleta F Theodoroula; Aggeliki Lampri; Eleni Mezarli; Anastasios Kartas; Dimitrios Chatzidimitriou; Anna Papa-Konidari; Eleftherios Angelis; Ηaralambos Karvounis; Georgios Sianos
Journal:  BMC Cardiovasc Disord       Date:  2021-06-08       Impact factor: 2.298

9.  Genetic information improves the prediction of major adverse cardiovascular events in the GENEMACOR population.

Authors:  Maria Isabel Mendonça; Eva Henriques; Sofia Borges; Ana Célia Sousa; Andreia Pereira; Marina Santos; Margarida Temtem; Sónia Freitas; Joel Monteiro; João Adriano Sousa; Ricardo Rodrigues; Graça Guerra; Roberto Palma Dos Reis
Journal:  Genet Mol Biol       Date:  2021-06-11       Impact factor: 1.771

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.